Enhertu's Efficacy and Safety Profile in HER2-Positive Metastatic Breast Cancer
Enhertu's Groundbreaking Role in Breast Cancer Treatment
Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-positive metastatic breast cancer has shown truly remarkable outcomes, with Dr. Nancy Lin discussing its efficacy and unique considerations at the 2024 ESMO Congress.
Results and Comparisons
In patients with previously untreated brain metastases, Enhertu's response rate reached an extraordinary 82%, with a median progression-free survival (PFS) exceeding 17 months and an overall survival after 12 months surpassing 90%.
- Tukysa (tucatinib), Xeloda (capecitabine), and Herceptin (trastuzumab): This regimen reported around 50% CNS response with a median PFS just over 7 months.
- Safety profiles differ significantly; while Enhertu may lead to increased nausea and the risk of interstitial lung disease, the standard regimen is associated with more diarrhea and hand-foot symptoms.
Patient-Centric Considerations
As treatment options expand, it’s vital to consider both efficacy and toxicity endpoints when counseling patients. For those aiming to retain their hair, the standard regimen may be preferable. Conversely, patients desiring a streamlined infusion process may opt for Enhertu.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.